共 28 条
Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancer
被引:23
作者:
Herrstedt, J
[1
]
Sigsgaard, T
[1
]
Handberg, J
[1
]
Schousboe, BMB
[1
]
Hansen, M
[1
]
Dombernowsky, P
[1
]
机构:
[1] CENT HOSP HILLEROD,DEPT MED F,HILLEROD,DENMARK
关键词:
D O I:
10.1200/JCO.1997.15.4.1690
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Purpose: To investigate the antiemetic effect and tolerability the 5-hydroxytryptamine(3) (5-HT3) antagonist ondansetron plus the dopamine D-2 antagonist metopimazine versus ondansetron alone in patients receiving platinum-based chemotherapy. Patients and Methods: One hundred eleven chemotherapy-naive patients who were scheduled to receive two consecutive courses of platinum-based chemotherapy were randomized between ondansetron 8 mg intravenously (IV) followed by 8 mg orally twice a day plus metopimazine 35 mg/m(2) as a 24-hour continuous infusion followed by 30 mg orally four times a day for 4 days, or ondansetron plus placebo. The study used a double-blind, crossover, placebo-controlled design. Results: Ninety-four patients completed the crossover, Complete response (CR; no emetic episodes) was obtained on day 1 in 77.7% of the patients who received the combination versus 50.0% of those who received ondansetron alone (P = .00002), and in 51.7% versus 31.0% on days 2 to 6 (P = .0009). The overall CR (days 1 to 6) was 48.9% versus 25.3% (P = .0002). Additionally, significantly less nausea was observed with the combination on day 1 (P = .0002), days 2 to 6 (P = .0001), and days 1 to 6 (P = .00004). Patient preference was 63.6% for the combination and 13.6% for ondansetron alone; 22.7% expressed no treatment preference (P < .0001; therapeutic gain 50.0%; 95% confidence interval [CI], 31.6% to 68.4%), Adverse reactions were mild and without significant differences between the two treatments. Conclusion: Metopimazine plus ondansetron was significantly superior to ondansetran alone, concerning all efficacy parameters assessed, in patients who received platinum-based chemotherapy. (C) 1991 by American Society of Clinical Oncology.
引用
收藏
页码:1690 / 1696
页数:7
相关论文